CpG site degeneration triggered by the loss of functional constraint created a highly polymorphic macaque drug-metabolizing gene, CYP1A2
© Uno and Osada; licensee BioMed Central Ltd. 2011
Received: 2 August 2011
Accepted: 1 October 2011
Published: 1 October 2011
Elucidating the pattern of evolutionary changes in drug-metabolizing genes is an important subject not only for evolutionary but for biomedical research. We investigated the pattern of divergence and polymorphisms of macaque CYP1A1 and CYP1A2 genes, which are major drug-metabolizing genes in humans. In humans, CYP1A2 is specifically expressed in livers while CYP1A1 has a wider gene expression pattern in extrahepatic tissues. In contrast, macaque CYP1A2 is expressed at a much lower level than CYP1A1 in livers. Interestingly, a previous study has shown that Macaca fascicularis CYP1A2 harbored unusually high genetic diversity within species. Genomic regions showing high genetic diversity within species is occasionally interpreted as a result of balancing selection, where natural selection maintains highly diverged alleles with different functions. Nevertheless many other forces could create such signatures.
We found that the CYP1A1/2 gene copy number and orientation has been highly conserved among mammalian genomes. The signature of gene conversion between CYP1A1 and CYP1A2 was detected, but the last gene conversion event in the simian primate lineage occurred before the Catarrhini-Platyrrhini divergence. The high genetic diversity of macaque CYP1A2 therefore cannot be explained by gene conversion between CYP1A1 and CYP1A2. By surveying CYP1A2 polymorphisms in total 91 M. fascicularis and M. mulatta, we found several null alleles segregating in these species, indicating functional constraint on CYP1A2 in macaques may have weakened after the divergence between humans and macaques. We propose that the high genetic diversity in macaque CYP1A2 is partly due to the degeneration of CpG sites, which had been maintained at a high level by purifying selection, and the rapid degeneration process was initiated by the loss of functional constraint on macaque CYP1A2.
Our findings show that the highly polymorphic CYP1A2 gene in macaques has not been created by balancing selection but by the burst of CpG site degeneration after loss of functional constraint. Because the functional importance of CYP1A1/2 genes is different between humans and macaques, we have to be cautious in extrapolating a drug-testing data using substrates metabolized by CYP1A genes from macaques to humans, despite of their somewhat overlapping substrate specificity.
Cytochrome P450 oxidase (CYP) proteins oxidize a wide variety of substrates. They could metabolize not only many endogenous substrates such as steroid hormones, but also exogenous toxins for excretion . In biomedical research, CYP are widely recognized as drug-metabolizing enzymes. Probably, normal function of drug-metabolizing CYPs in natural habitats would be detoxication of xenophobic chemicals taken from foods, especially from plants .
Humans have about 60 CYP genes in the genome . Among them, CYP1A gene subfamily is one of the most major CYP subfamilies in humans. The human genome contains two CYP1A genes on chromosome 15, CYP1A1 and CYP1A2, which are tandemly aligned with 23-kb interval and head-to-head orientation . The amino acid sequence identity between the paralogs is > 80% and their protein structures are supposed to be very similar, partly accounting for overlapping substrate selectivity of these enzymes . Human CYP1A2 is constitutively expressed in livers and contributes to the hepatic metabolism of many important chemical compounds such as caffeine . In contrast, the tissue distribution of human CYP1A1 gene expression is very broad and its expression is strongly induced by exogenous compounds, indicating CYP1A2 rather than CYP1A1 is a major hepatic CYP1A gene in humans. Polymorphisms in human CYP1A genes have been intensively studied for medical benefits (e.g., ), while a few studies from an evolutionary standpoint have been conducted for human CYP1A genes [8, 9]. For example, Jorge-Nebert et al. surveyed the pattern of single nucleotide polymorphisms (SNPs) in several human populations at the CYP1A1-CYP1A2 locus and found the signature of selective sweep around the CYP1A1 untranslated region . However, the role of the selective sweep for human CYP1A1 evolution remains unclear.
Because macaque monkeys are widely used for testing drug toxicity in preclinical trials, the genetic similarity of CYP genes between humans and macaques is important not only for evolutionary research but also for biomedical applications . Unexpected phenotypic difference between divergent species is one the biggest concerns in drug development, e.g., . A previous study has suggested that drug metabolism by CYP1A1/2 was not perfectly conserved among humans, macaques, and marmosets . Elucidating the cause of phenotypic differences among primates at a genetic level is an important task.
Our previous sequence analysis showed that the region encompassing the first intron and exon 2 of macaque CYP1A2 had the highest genetic diversities among randomly selected 54 unlinked autosomal loci . Because allelic variation of CYP1A2 proteins may increase a repertory of toxic substrates metabolized by CYP1A2, it is reasonable to imagine that the high genetic diversity in macaque CYP1A2 has been maintained by balancing selection, where natural selection maintains highly diverged alleles having different functions [14, 15]. However, other studies also have shown that the gene expression pattern of CYP1A2 in macaques was quite different from that in humans. The level of gene expression of macaque CYP1A2 is very low in all Macaca fascicularis (cynomolgus macaques) livers so far examined [16, 17]. The expression level of CYP1A1 is instead much more abundant in macaque livers. Interestingly, the pattern of CYP1A1/2 protein expression appears similar between humans and marmosets , indicating a major hepatic CYP1A gene was switched at some time after the divergence of the human and macaque lineages . The result casts doubt that the balancing selection hypothesis accounts for high CYP1A2 diversity in macaques. However, if macaque CYP1A2 lost its function, the evolutionary history of CYP1A2 should resemble many other neutral loci.
In order to answer the question why macaque CYP1A2 has unusually high genetic diversity, we first investigated the long-term evolution pattern of CYP1A subfamily. Gene conversion between paralogs was examined with particular attention, because gene conversion between paralogs may create an unusual pattern of polymorphisms in paralogous genes. We found that the last gene conversion event between CYP1A1 and CYP1A2 in the lineages to Catarrhini primates occurred after the divergence of primates and rodents, and before the divergence of Catarrhini and Platyrrhini primates. We further sequenced CYP1A1/2 coding regions of 63 M. fascicularis and 28 M. mulatta individuals, and found several deletions and single nucleotide polymorphisms in macaque CYP1A2 with relatively high frequencies, which cause premature stop codons. We propose that macaque CYP1A2 is in the process of pseudogenization, and rapid degeneration of CpG sites is creating a high genetic diversity.
Phylogenetic analysis of mammalian CYP1A subfamily
We also investigated whether macaques carry additional copy of CYP1A genes other than CYP1A1/2 in the genome. The latest draft genome sequence of M. mulatta (rheMac2) did not contain any other sequence similar to CYP1A. Furthermore, a previous search for genes expressed in M. fascicularis livers did not identify any additional macaque CYP1A paralogs , suggesting that CYP1A1 and CYP1A2 are the only CYP1A genes in macaque genomes.
Gene conversion between CYP1A1 and CYP1A2
Amino acid p-distance between human-mouse CYP1A1/2 quartets
Genetic diversity of CYP1 genes in M. fascicularis
Genetic diversity of M.fascicularis CYP1A1/2 genes
In those samples, four null mutations were segregating in M. fascicularis CYP1A2. If the function of CYP1A2 were completely lost before the most recent common ancestor (MRCA) of macaques, mutations would be randomly segregating at nonsynonymous and synonymous sites and the ratio of per-site nucleotide diversity at nonsynonymous site to synonymous sites (πA/πS) would be close to 1. The ratio of nonsynonymous nucleotide diversity (πA) to synonymous nucleotide diversity (πS) in CYP1A2 was 0.51, much smaller than 1, although larger than the ratio in CYP1A1 (πA/πS = 0.12). The ratio smaller than 1 indicates that the CYP1A2 gene in macaques lost its function after the occurrence of MRCA, or the function of CYP1A2 is partly retained: i.e., null alleles have been weakly selected against in macaque CYP1A2. When we analyzed only individuals that have both CYP1A1 and CYP1A2 sequences (12 chromosomes), the estimated values of π were similar to the values with all samples (0.00075 and 0.00442 in M. fascicularis CYP1A1 and CYP1A2, respectively).
In order to investigate whether the different pattern of genetic diversity between CYP1A1 and CYP1A2 genes are simply due to difference in functional constraint and/or mutation rates, HKA tests were conducted using human orthologous genes as outgroup genes . M. fascicularis individuals having both CYP1A1 and CYP1A2 sequences were analyzed and the test was significant (P = 0.0415), indicating macaque CYP1A2 has relatively high polymorphism given the level of divergence. The marginal significance in M. fascicularis was improved (P = 0.0224) when an additional eight M. mulatta chromosomes were analyzed together.
Resequencing of a large number of M. fascicularis and M. mulatta CYP1A2
Allele frequency of null alleles in macaque CYP1A2
Position in coding sequence
G to A
1 bp deletion
C to T
C to T
T to A
Interestingly, 32 of 65 SNPs were at CpG dinucleotide sites. It is well known that methylated dinucleotide CG tends to mutate to CA and TG in mammalian genomes, probably at > 10 times faster than the background mutation rate [24, 25]. In agreement with this prediction, 30 of 32 mutations at CpG sites were mutations from CG to CA or from CG to TG, assuming human CYP1A2 had ancestral alleles. Among those mutations, 20, 9, and 1 were synonymous, nonsynonymous, and null mutations, respectively. We counted the number of CpG dinucleotides in the reference M. fascicularis CYP1A1/2 cDNA sequences (CYP1A1, D17575; CYP1A2, D86474). Macaque CYP1A1 and CYP1A2 had 41 and 63 CpG dinucleotides in the protein coding regions, respectively; the macaque CYP1A2 contained CpG sites about 8% of the coding sequence. Among all annotated genes in the M. mulatta genome sequence (RefSeq genes, ), the fraction of CpG sites in CYP1A2 was ranked in the upper 8.3%.
Natural selection on drug-metabolizing genes
The process of drug metabolism has been under intense studies for biomedical benefits. Because humans are only natural organisms utilizing so-called "drugs", the impact of natural selection on drug metabolizing genes still remains unclear, except for some cases of insect herbivores specialized to their host plants [28, 29]. Considering that many plant secondary metabolites are oxidized by CYP proteins and endogenous substrates controlling physiology such as hormones are also metabolized by CYP proteins, it is straightforward to access the effect of natural selection on the CYP protein diversity. For example, Thompson et al. proposed that the natural variation in human CYP3A5 is related to the retention of salt in a body and under natural selection according to latitudes . A scan of recent selective sweeps in the human genome also detected a significant excess of CYP genes among those regions . In macaques, Osada et al. found that CYP3A5 gene was highly differentiated between M. fascicularis and M. mulatta compared with other genes, suggesting the action of natural selection on the gene for local adaptation . In the same study, they also found that CYP1A2 contained unusually high genetic diversity within the macaque species. Although the previous studies have revealed a weak hepatic expression of macaque CYP1A2, the weak expression does not necessary imply that macaque CYP1A2 is not biologically important. The main object of this study is elucidating the mode of natural selection on macaque CYP1A2.
Gene conversion between CYP1A genes and effect on substrate specificity
Because many factors, including gene conversion between paralogous genes, could create highly polymorphic genes, we first clarified the pattern of molecular evolution of the CYP1A subfamily. Whether CYP1A subfamily may have expanded or contracted many times through the process of birth-and-death evolution of gene families , is an interesting question. For example, in CYP2D subfamily, lineage-specific gene losses in primates were reported , but the subfamily also experienced a large-scale expansion in non-primate placental mammals. We found that many vertebrate species genomes encoded CYP1A1 and CYP1A2 with the same head-to-head orientation as the human genome, and macaques did not harbor any other paralogous CYP1A genes created by recent gene duplication. A new method combining a window plot and maximum likelihood successfully detected the signature of gene conversion at the first 500 bp of exon 2 and entire exon 5, which correspond to SRS1 and SRS5, respectively. Our method is not sensitive to gene conversion tracts much shorter than the window size (150 bp), but successfully detected the gene conversion events in those regions. In addition, we did not find any signature of gene conversion using human and marmoset genes, indicating the last gene conversion event occurred before the divergence of Catarrhini and Platyrrhini. Because gene conversion is supposed to work effectively on young duplicates , we expect the two paralogs in primates continue diverging since gene conversion ceased. Interestingly, one amino acid at position 382 in SRS5 is responsible for substrate specificity of CYP1A1/2 gene to 7-ethoxyresorufin (382V) and 7-ethoxyresorufin (382L) . The last gene conversion homogenized SRS5 of CYP1A1 and CYP1A2 and the substrate specificity should have been acquired after the event. Indeed, both macaque CYP1A1 and CYP1A2 proteins have 382V, but orangutan has 382V in CYP1A1 and 382L in CYP1A2, indicating that the mutation from valine to leucine that modified the substrate specificity fixed after the divergence of human and macaque lineages and before the divergence of human and orangutan lineages. In contrast to exon 2 and 5, the other exons showed much higher paralogous divergence. The regional heterogeneity of gene conversion pattern may indicate natural selection diversifying the substrate specificities of CYP1A1 and CYP1A2 has been maintaining the high paralogous divergence in those conversion-repressed regions, as shown in the cases of Drosophila transporter genes and yeast heat shock protein genes [36, 37].
CYP1A2 gene is dispensable in macaques
In contrast to our initial expectation, we found many null alleles were segregating both in M. fascicularis and M. mulatta CYP1A2. The highest allele frequency of these null alleles was 39% at site 1066 in M. mulatta (Table 3). Although we previously identified two null alleles in macaque CYP3A4 and CYP3A5, the null allele frequencies were less than 1% , indicating the null variants in CYP3A4/5 are strongly selected against by natural selection in contrast to CYP1A2. Because all M. fascicularis so far examined had weak gene expression of CYP1A2, mutations in regulatory regions should have become fixed in the common ancestors of macaques. However, it remains unclear whether the initial loss of gene expression was driven by positive selection under the "less is more" hypothesis , or due to the fixation of neutral or slightly deleterious alleles.
Mechanisms of rapid decay of CpG sites
If macaque CYP1A2 gene is losing its function, why do we observe the high genetic diversity in populations? Although loss-of-function generally results in evolutionary patterns similar to patterns under neutrality, the genetic diversity in macaque CYP1A2 was significantly higher than CYP1A1, and much higher than the previously investigated background loci . We found that primate CYP1A2 genes contained a considerable number of CpG sites, which are thought to mutate at much higher rates than other sites.
A number of mammalian genome studies have revealed that CpG sites are enriched in genic regions not only at nonsynonymous sites such as encoding arginine, but also at synonymous sites and introns. The reason why genic regions in mammalian genomes are enriched with CpG sites is not totally clear, but we could raise two hypotheses. One is the natural selection hypothesis, where natural selection is maintaining CpG sites within genes for the control of transcriptional regulation or integrity of genomes . Another is the substitution bias hypothesis, where biased gene conversion is maintaining high GC content in genic regions  because of the association between recombination and gene density . In particular, it was proposed that inter-locus gene conversion among multi-gene family members could increase CG content of those genes . Although the latter mechanism would be important for creating the high GC regions in genomes, it cannot explain the deficiency of CpG degeneration in genic regions (Figure 3B), because under the substitution bias hypothesis we should observe many gain of CG as well as loss of CpG in genic regions. Therefore, at some extent, purifying selection protecting CpG sites within genic regions must play an essential role for maintaining CpG sites.
There are two ways how natural selection is protecting CpG sites from degeneration. Firstly, natural selection could keep CpG sites as unmethylated status in germ line cells, which can be observed in CpG-island associated genes. Secondly, CpG sites are methylated in germ line cells and tend to degenerate, but the degenerated alleles are removed from populations by purifying selection. Unfortunately, we could not determine which scenario is more plausible in the case of macaque CYP1A2 gene. Future studies investigating the methylation pattern within human and macaque CYP1A genes in many tissues would answer such questions. With either scenario, we could predict that once genes with many CpG sites lose its function, those genes would start to accumulate many mutations caused by rapid CpG degeneration.
Effect of CpG site degeneration at species divergence level
In this study, our main focus was the effect of CpG degeneration on genetic diversity within species. However, the same caution should be taken in analyses between two diverged species, as suggested by Subramanian and Kumar . As an extreme case, imagine a gene encoding many arginine residues. If the gene lost its function and those sites are methylated, many CpG sites start to degenerate and we would observe the acceleration of nonsynonymous changes relative to synonymous changes. Such pattern is often interpreted as the signature of positive selection, but we need to be careful for interpreting such data [45–47]. Indeed, when we compare the coding sequences of human and M. fascicularis reference CYP1A2 sequences, the ratio of non-synonymous substitution rate to synonymous substitution rate was 0.445, which was nearly two times higher than the genome-wide average , indicating that, although weakly, CpG degeneration affects the evolution rate of CYP1A2 at the apparent species divergence level.
Our molecular evolution and population genetic study strongly supports that macaque CYP1A2 is no longer essential for M. fascicularis and M. mulatta. At some time after the divergence between humans and macaques, the major hepatic CYP1A gene was changed in the lineage to macaques. However, CYP1A1 gene expression pattern in macaques has not been completely switched to the human CYP1A2 expression pattern; the expression of macaque CYP1A1 is not so abundant without induction, but strongly induced by omeprazole, a CYP inducer [49, 50]. The alteration of gene expression pattern could be possible by changes in the gene regulatory region, because CYP1A1 and CYP1A2 are aligned in a head-to-head orientation and shared a promoter region . At this moment, we do not have any hypothesis explaining why the change of expression pattern and loss of function occurred only in the macaque lineage. Since the last gene conversion events between CYP1A1 and CYP1A2 occurred before the divergence between Catarrhini and Platyrrhini, the resurrection of function by gene conversion cannot explain the macaque-specific gene loss. Because the functional importance of CYP1A1/2 genes is highly different between humans and macaques, we have to be cautious in extrapolating a drug-testing data using substrates metabolized by CYP1A genes from macaques to humans, despite of their somewhat overlapping substrate specificities.
DNA sequences of vertebrate CYP1A1/2 genes were retrieved from a public database, and analyzed using MEGA 5 . DDBJ/EMBL/Genbank accession numbers of analyzed cDNA sequences are as follows: macaque CYP1A1 (D17575), macaque CYP1A2 (D86474), mouse CYP1A1 (AK005000), mouse CYP1A2 (BC018298), rat CYP1A1 (X00469), rat CYP1A2 (BC127476), chicken CYP1A4 (X99453), chicken CYP1A5 (X99454), and medaka CYP1A (AY297923). The nucleotide sequences were aligned using the MUSCLE with default parameter setting using the information of amino acid sequences . The phylogenetic tree of CYP1A1/2 was constructed using the amino acid sequences with the Dayhoff's distance matrix and the bootstrap resampling was performed 1000 times.
Test of gene conversion
Quartet sequences (two paralogous genes from two different species) were used to detect the molecular evolution pattern under gene conversion. The nucleotide sequence alignments of exon 2, 3, and 7 were binned into 150-bp-length windows with 9 bp incremental steps. Because the nucleotide sequence alignments of exon 4, 5, and 6 were shorter than 150 bp, they were analyzed as single windows. For each window, we estimated the log-likelihood values of the type-N and type-C trees using PAML .
Resequencing of macaque CYP1A1/2 genes
Whole blood was collected from 63 cynomolgus macaques (31 from Indochina and 32 from Indonesia, 3-8 years of age, 3-5 kg) and 28 rhesus macaques (from China, 2-3 years of age, weighing 3-5 kg). Genomic DNA was prepared from these blood samples using Gentra Puregene Blood kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The study was reviewed and approved by the Institutional Animal Care and Use Committee of Shin Nippon Biomedical Laboratories, Ltd (Kainan, Japan). Polymorphisms were identified by PCR amplification, followed by direct-sequencing. Briefly, PCR was performed in a 20 μL reaction containing 1 ng of genomic DNA, 5 pmole of each primer, and 1 unit of AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA) using a thermal cycler (Applied Biosystems). For exons 2-5 of CYP1A1, EX Taq HS DNA polymerase (Takara, Tokyo, Japan) was used. Thermal cycler condition included an initial denaturation at 95°C for 10 min: 30 cycles of 20 s at 95°C, 30 s at 55-60°C, and 1 min at 72°C, followed by a final extension step of 5 min at 72°C. PCR products were sequenced using an ABI PRISM BigDye Terminator v3.0 Ready Reaction Cycle Sequencing Kit (Applied Biosystems), followed by electrophoresis on an ABI PRISM 3730 DNA Analyzer (Applied Biosystems). PCR/sequencing primers and annealing temperatures for PCR are listed in Table S1 (Additional File 1).
List of abbreviations
cytochrome oxidase P450
single nucleotide polymorphism.
We would like to thank Dr. Hiroshi Akashi for comments and editing the manuscript and Mr. Akinori Matsushita for technical assistance. We wish to acknowledge valuable comments from three anonymous reviewers. This study was supported by Grant-in-Aid for Scientific Research on Innovative Areas (23113001 and 23113008) to N. O..
- Anzenbacher P, Anzenbacherová E: Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001, 58 (5): 737-747. 10.1007/PL00000897.View ArticlePubMed
- Dearing MD, Foley WJ, Mclean S: The influence of plant secondary metabolites on the nutritional ecology of herbivorous terrestrial vertebrates. Annu Rev Ecol Evol Syst. 2005, 36: 169-189. 10.1146/annurev.ecolsys.36.102003.152617.View Article
- Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenet Genomics. 2004, 14 (1): 1-18.View Article
- Corchero J, Pimprale S, Kimura S, Gonzalez FJ: Organization of the CYP1A cluster on human chromosome 15: Implications for gene regulation. Pharmacogenet Genomics. 2001, 11 (1): 1-6.View Article
- Morrison HG, Weil EJ, Karchner SI, Sogin ML, Stegeman JJ: Molecular cloning of CYP1A from the estuarine fish fundulus heteroclitus and phylogenetic analysis of CYP1 genes: Update with new sequences. Comp Biochem Phys C. 1998, 121 (1-3): 231-240.
- Omiecinski CJ, Remmel RP, Hosagrahara VP: Concise review of the cytochrome P450s and their roles in toxicology. Toxicol Sci. 1999, 48 (2): 151-156. 10.1093/toxsci/48.2.151.View ArticlePubMed
- Amos CI, Caporaso NE, Weston A: Host factors in lung cancer risk: A review of interdisciplinary studies. Cancer Epidem Biomar. 1992, 1 (6): 505-513.
- Browning SL, Tarekegn A, Bekele E, Bradman N, Thomas MG: CYP1A2 is more variable than previously thought: A genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics. 2010, 20 (11): 647-664. 10.1097/FPC.0b013e32833e90eb.View ArticlePubMed
- Jorge-Nebert LF, Jiang Z, Chakraborty R, Watson J, Jin L, Mcgarvey ST, Deka R, Nebert DW: Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations. Hum Mutat. 2010, 31 (1): 27-40. 10.1002/humu.21132.View ArticlePubMedPubMed Central
- Uno Y, Iwasaki K, Yamazaki H, Nelson DR: Macaque cytochromes P450: Nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev. 2011, 1-16.
- Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006, 355 (10): 1018-1028. 10.1056/NEJMoa063842.View ArticlePubMed
- Edwards RJ, Murray BP, Murray S, Schulz T, Neubert D, Gant TW, Thorgeirsson SS, Boobis AR, Davies DS: Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis. 1994, 15 (5): 829-836. 10.1093/carcin/15.5.829.View ArticlePubMed
- Osada N, Uno Y, Mineta K, Kameoka Y, Takahashi I, Terao K: Ancient genome-wide admixture extends beyond the current hybrid zone between Macaca fascicularis and M. mulatta. Mol Ecol. 2010, 19 (14): 2884-2895. 10.1111/j.1365-294X.2010.04687.x.View ArticlePubMed
- Levene H: Genetic equilibrium when more than one ecological niche is available. Am Nat. 1953, 87 (836): 331-333. 10.1086/281792.View Article
- Charlesworth D: Balancing selection and its effects on sequences in nearby genome regions. PLoS Genet. 2006, 2 (4): e64-10.1371/journal.pgen.0020064.View ArticlePubMedPubMed Central
- Sakuma T, Hieda M, Igarashi T, Ohgiya S, Nagata R, Nemoto N, Kamataki T: Molecular cloning and functional analysis of cynomolgus monkey CYP1A2. Biochem Pharmacol. 1998, 56 (1): 131-139. 10.1016/S0006-2952(98)00100-2.View ArticlePubMed
- Uno Y, Uehara S, Murayama N, Yamazaki H: CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey. Biochem Pharmacol. 2011, 81 (3): 442-450. 10.1016/j.bcp.2010.11.003.View ArticlePubMed
- Goldstone H, Stegeman J: A revised evolutionary history of the CYP1A subfamily: Gene duplication, gene conversion, and positive selection. J Mol Evol. 2006, 62 (6): 708-717. 10.1007/s00239-005-0134-z.View ArticlePubMed
- Benton MJ: Phylogeny of the major tetrapod groups: Morphological data and divergence dates. J Mol Evol. 1990, 30 (5): 409-424. 10.1007/BF02101113.View ArticlePubMed
- Kumar S, Hedges SB: A molecular timescale for vertebrate evolution. Nature. 1998, 392 (6679): 917-920. 10.1038/31927.View ArticlePubMed
- Uno Y, Suzuki Y, Wakaguri H, Sakamoto Y, Sano H, Osada N, Hashimoto K, Sugano S, Inoue I: Expressed sequence tags from cynomolgus monkey (Macaca fascicularis) liver: A systematic identification of drug-metabolizing enzymes. FEBS Lett. 2008, 582 (2): 351-358. 10.1016/j.febslet.2007.12.031.View ArticlePubMed
- Yang Z: PAML 4: Phylogenetic analysis by maximum likelihood. Mol Biol Evol. 2007, 24 (8): 1586-1591. 10.1093/molbev/msm088.View ArticlePubMed
- Hudson RR, Kreitman M, Aguade M: A test of neutral molecular evolution based on nucleotide data. Genetics. 1987, 116 (1): 153-159.PubMedPubMed Central
- Elango N, Kim S-H, Vigoda E, Yi SV, Program NCS: Mutations of different molecular origins exhibit contrasting patterns of regional substitution rate variation. PLoS Comput Biol. 2008, 4 (2): e1000015-10.1371/journal.pcbi.1000015.View ArticlePubMedPubMed Central
- Roach JC, Glusman G, Smit AFA, Huff CD, Hubley R, Shannon PT, Rowen L, Pant KP, Goodman N, Bamshad M, et al: Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science. 2010, 328 (5978): 636-639. 10.1126/science.1186802.View ArticlePubMedPubMed Central
- Maglott D, Ostell J, Pruitt KD, Tatusova T: Entrez Gene: Gene-centered information at NCBI. Nucleic Acids Res. 2011, 39 (suppl 1): D52-D57.View ArticlePubMedPubMed Central
- Bernardi G: Isochores and the evolutionary genomics of vertebrates. Gene. 2000, 241 (1): 3-17. 10.1016/S0378-1119(99)00485-0.View ArticlePubMed
- Naumann C, Hartmann T, Ober D: Evolutionary recruitment of a flavin-dependent monooxygenase for the detoxification of host plant-acquired pyrrolizidine alkaloids in the alkaloid-defended arctiid moth Tyria jacobaeae. Proc Natl Acad Sci USA. 2002, 99 (9): 6085-6090. 10.1073/pnas.082674499.View ArticlePubMedPubMed Central
- Li X, Baudry J, Berenbaum MR, Schuler MA: Structural and functional divergence of insect CYP6B proteins: From specialist to generalist cytochrome P450. Proc Natl Acad Sci USA. 2004, 101 (9): 2939-2944. 10.1073/pnas.0308691101.View ArticlePubMedPubMed Central
- Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A: CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet. 2004, 75 (6): 1059-1069. 10.1086/426406.View ArticlePubMedPubMed Central
- Voight BF, Kudaravalli S, Wen X, Pritchard JK: A map of recent positive selection in the human genome. PLoS Biol. 2006, 4 (3): e72-10.1371/journal.pbio.0040072.View ArticlePubMedPubMed Central
- Nei M, Rooney AP: Concerted and birth-and-death evolution of multigene families. Annu Rev Genet. 2005, 39: 121-152. 10.1146/annurev.genet.39.073003.112240.View ArticlePubMedPubMed Central
- Yasukochi Y, Satta Y: Evolution of the CYP2D gene cluster in humans and four non-human primates. Genes Genet Syst. 2011, 86 (2): 109-116. 10.1266/ggs.86.109.View ArticlePubMed
- Teshima KM, Innan H: The effect of gene conversion on the divergence between duplicated genes. Genetics. 2004, 166 (3): 1553-1560. 10.1534/genetics.166.3.1553.View ArticlePubMedPubMed Central
- Liu J, Ericksen SS, Sivaneri M, Besspiata D, Fisher CW, Szklarz GD: The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch Biochem Biophys. 2004, 424 (1): 33-43. 10.1016/j.abb.2003.12.040.View ArticlePubMed
- Osada N, Innan H: Duplication and gene conversion in the drosophila melanogaster genome. PLoS Genet. 2008, 4 (12): e1000305-10.1371/journal.pgen.1000305.View ArticlePubMedPubMed Central
- Takuno S, Innan H: Selection to maintain paralogous amino acid differences under the pressure of gene conversion in the heat-shock protein genes in yeast. Mol Biol Evol. 2009, 26 (12): 2655-2659. 10.1093/molbev/msp211.View ArticlePubMed
- Uno Y, Matsushita A, Osada N, Uehara S, Kohara S, Nagata R, Fukuzaki K, Utoh M, Murayamay N, Yamazaki H: Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab Dispos. 2010, 38 (2): 209-214. 10.1124/dmd.109.029710.View ArticlePubMed
- Olson MV: When less is more: Gene loss as an engine of evolutionary change. The Am J Hum Genet. 1999, 64 (1): 18-23. 10.1086/302219.View ArticlePubMed
- Cross SH, Bird AP: CpG islands and genes. Curr Opin Genet Dev. 1995, 5 (3): 309-314. 10.1016/0959-437X(95)80044-1.View ArticlePubMed
- Galtier N, Duret L: Adaptation or biased gene conversion? Extending the null hypothesis of molecular evolution. Trends Genet. 2007, 23 (6): 273-277. 10.1016/j.tig.2007.03.011.View ArticlePubMed
- Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, Sigurdardottir S, Barnard J, Hallbeck B, Masson G, et al: A high-resolution recombination map of the human genome. Nat Genet. 2002, 31 (3): 241-247.PubMed
- Galtier N: Gene conversion drives gc content evolution in mammalian histones. Trends Genet. 2003, 19 (2): 65-68. 10.1016/S0168-9525(02)00002-1.View ArticlePubMed
- Subramanian S, Kumar S: Neutral substitutions occur at a faster rate in exons than in noncoding DNA in primate genomes. Genome Res. 2003, 13 (5): 838-844. 10.1101/gr.1152803.View ArticlePubMedPubMed Central
- Hughes AL: Looking for Darwin in all the wrong places: The misguided quest for positive selection at the nucleotide sequence level. Heredity. 2007, 99 (4): 364-373. 10.1038/sj.hdy.6801031.View ArticlePubMed
- Subramanian S, Kumar S: Higher intensity of purifying selection on > 90% of the human genes revealed by the intrinsic replacement mutation rates. Mol Biol Evol. 2006, 23 (12): 2283-2287. 10.1093/molbev/msl123.View ArticlePubMedPubMed Central
- Suzuki Y, Gojobori T, Kumar S: Methods for incorporating the hypermutability of CpG dinucleotides in detecting natural selection operating at the amino acid sequence level. Mol Biol Evol. 2009, 26 (10): 2275-2284. 10.1093/molbev/msp133.View ArticlePubMedPubMed Central
- Wang HY, Chien HC, Osada N, Hashimoto K, Sugano S, Gojobori T, Chou CK, Tsai SF, Wu CI, Shen CK: Rate of evolution in brain-expressed genes in humans and other primates. PLoS Biol. 2007, 5: e13-10.1371/journal.pbio.0050013.View ArticlePubMedPubMed Central
- Nishimura M, Koeda A, Suganuma Y, Suzuki E, Shimizu T, Nakayama M, Satoh T, Narimatsu S, Naito S: Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab Pharmacokinet. 2007, 22 (3): 178-186. 10.2133/dmpk.22.178.View ArticlePubMed
- Ise R, Uehara S, Akiyama H, Kondo S, Iwasaki K, Nagata R, Nobumasa H, Yamazaki H, Uno Y: A newly developed DNA microarray is useful to assess induction of cytochromes P450 in cynomolgus monkey. Drug Metab Pharmacokinet. 2011, 26 (3): 228-235. 10.2133/dmpk.DMPK-10-RG-099.View ArticlePubMed
- Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011, 28 (10): 2731-2739. 10.1093/molbev/msr121.View ArticlePubMedPubMed Central
- Edgar RC: MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32 (5): 1792-1797. 10.1093/nar/gkh340.View ArticlePubMedPubMed Central
- Librado P, Rozas J: DnaSP v5: A software for comprehensive analysis of DNA polymorphism data. Bioinformatics. 2009, 25 (11): 1451-1452. 10.1093/bioinformatics/btp187.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.